Secukinumab receives expanded approvals in EU for pediatric arthritic conditionsJuly 5th 2022
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
Provocative poster sessions abound at the SPD 2022 47th Annual MeetingJuly 3rd 2022
You will find dermatologic studies from the rare (annual erythema of infancy) to the common (atopic dermatitis) and lots in between at the poster sessions at this year's SPD 2022 47th Annual Meeting in Indianapolis, Indiana.
Dermatological conditions and the relationship to self-imageJuly 2nd 2022
It is important for pediatric and family nurse practitioners caring for patients with dermatological conditions to be comfortable talking about the conditions with children, adolescents, and their parents.
Optimize outcomes for pediatric patients who need infusion therapyJune 20th 2022
Robert Dracker, MD, MHA, MBA, CPI, discussed considerations and developmentally appropriate interventions to promote high quality, patient-centered pediatric infusion care in a presentation at the 2022 National Infusion Center Association Annual Conference.